Neuro

Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.

Retrieved on: 
Monday, August 15, 2022
Woman, Regulation of tobacco by the U.S. Food and Drug Administration, Nasdaq, RAD1901, Industry, GLOBE, Gurnet Point, Massachusetts, Investment, Sale, Prader–Willi syndrome, Man, Acquisition, Spasm, Partnership, Angelman syndrome, Abaloparatide, Health, Fracture, Neuro, Food, Osteoporosis, Pharmaceutical industry, Radius

CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Gurnet Point Capital (Gurnet Point) and Patient Square Capital (Patient Square) announced today the completion of their acquisition of Radius Health, Inc. (Nasdaq: RDUS) (Radius).

Key Points: 
  • CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Gurnet Point Capital (Gurnet Point) and Patient Square Capital (Patient Square) announced today the completion of their acquisition of Radius Health, Inc. (Nasdaq: RDUS) (Radius).
  • Pursuant to the terms of the merger agreement, the purchaser entity for Gurnet Point and Patient Square merged with and into Radius, and as a result, Radius has become a wholly-owned indirect subsidiary of Gurnet Point and Patient Square.
  • Gurnet Point Capital is a leading healthcare fund that invests in de-risked life sciences companies.
  • Patient Square invests in businesses that strive to improve patient lives, strengthen communities and create a healthier world.

 Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer

Retrieved on: 
Thursday, August 11, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, FDA, Death, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Fulvestrant, Woman, PDUFA, HIV disease progression rates, Risk, RAD1901, NDA, Inflammation, ORR, Diagnosis, Population, Blastic plasmacytoid dendritic cell neoplasm, Clinical trial, Cancer, Menarini, Cardiology, CDK, European Medicines Agency, ESR1, Prader–Willi syndrome, Man, Patient, Review, MAA, Infection, Research and development, Breast cancer, Spasm, Angelman syndrome, SERD, SOC, Safety, NASDAQ, Priority review, Research, Mutation, DOR, PFS, Fast Track, Gastroenterology, Progression-free survival, Neuro, New Drug Application, Analgesic, Fracture, Food, Development, Osteoporosis, EMA, Pharmaceutical industry, Radius, Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology

The FDA has granted the application Priority Review and assigned a PDUFA date of February 17, 2023.

Key Points: 
  • The FDA has granted the application Priority Review and assigned a PDUFA date of February 17, 2023.
  • The FDAs acceptance of our NDA with Priority Review marks an important regulatory milestone for our company, commented Elcin Barker Ergun, Chief Executive Officer of the Menarini Group.
  • Elacestrant is an investigational selective estrogen receptor degrader (SERD), which is being evaluated for potential use as a once-daily oral treatment in patients with ER+/ HER2- advanced or metastatic breast cancer.
  • The EMERALD Phase 3 trial is a randomized, open label, active-controlled study evaluating elacestrant as second- or third-line monotherapy in ER+/HER2- advanced/metastatic breast cancer patients.

Hyperfine Reports Second Quarter 2022 Financial Results

Retrieved on: 
Wednesday, August 10, 2022
FDA, High-dependency unit, PST, Interim, CEO, GLOBE, Growth, Geography, Hospital, Health, Income, Marketing, Patient, Paola Lattus, DL, Partnership, Deep learning, Decision-making, Awareness, Research, Intensive care unit, Magnetic resonance imaging, Time, Neuro, MRI, Adoption, Video game, Reinsurance, Animal, Renewable energy, Medical imaging, Swoop, Hyperfine structure

Revenues for the second quarter of 2022 were $1.533 million, compared to $0.358 million in the second quarter of 2021.

Key Points: 
  • Revenues for the second quarter of 2022 were $1.533 million, compared to $0.358 million in the second quarter of 2021.
  • Gross margin for the second quarter of 2022 was $(0.165) million, compared to $(0.099) million in the second quarter of 2021.
  • Research and development expenses for the second quarter of 2022 were $7.265 million, compared to $6.037 million in the second quarter of 2021.
  • Sales, marketing, general, and administrative expenses for the second quarter of 2022 were $15.762 million, compared to $8.450 million in the second quarter of 2021.

Trilogy Health Services partners with Norton Healthcare to provide neuro stroke and spine rehab services

Retrieved on: 
Tuesday, August 9, 2022
Multimedia, FORTUNE, Norton Healthcare, Walgreens, Spine, Leadership, Cancer, Hospital, Patient, Stroke, Geriatrics, View, Ageing, Partnership, Neuroscience, Transition, Culture, Physician, Trilogy, Greater Louisville Inc., National Association Medical Staff Services, Heart, Neuro, Bed, Adult, Organization, Medicine, Glassdoor

LOUISVILLE, Ky., Aug. 9, 2022 /PRNewswire/ -- A new partnership between Trilogy Health Services and Norton Healthcare offers continuity of care for patients requiring in-patient rehab following neuro treatment for stroke and spine conditions.

Key Points: 
  • LOUISVILLE, Ky., Aug. 9, 2022 /PRNewswire/ -- A new partnership between Trilogy Health Services and Norton Healthcare offers continuity of care for patients requiring in-patient rehab following neuro treatment for stroke and spine conditions.
  • Westport Place Health Campus will also support patients who are in need of care and rehab after a suffering a stroke.
  • "Norton Healthcare is committed to providing excellent neuro care for stroke and spine patients."
  • Trilogy and Norton leaders held a ribbon cutting ceremony Tuesday, officially opening the unit at Westport Place Health Campus.

First expandable deep brain access port now available to neurosurgeons after successful human use

Retrieved on: 
Tuesday, August 9, 2022
University of Cincinnati Academic Health Center, Surgeon, Tulane University, Cancer, Patient, Quality of life, Stroke, SAINT, Partnership, GLARE, University, Central U.S. hardwood forests, Neurosurgery, Neuro, Iron ore, Medical imaging

SAINT PAUL, Minn., Aug. 9, 2022 /PRNewswire/ -- The Cerevention™ MindsEye™ Expandable Port, the world's first minimally invasive, expandable port providing deep brain access and visualization during surgical treatment of stroke, cancer, and other conditions, is now on the market, after successful human use. Mizuho America has secured an exclusive agreement to distribute the MindsEye expandable port to neurosurgeons in the U.S.

Key Points: 
  • Mizuho brings the Cerevention MindsEye Expandable Port to the U.S. market
    SAINT PAUL, Minn., Aug. 9, 2022 /PRNewswire/ -- The Cerevention MindsEye Expandable Port, the world's first minimally invasive, expandable port providing deep brain access and visualization during surgical treatment of stroke, cancer, and other conditions, is now on the market, after successful human use.
  • Mizuho America has secured an exclusive agreement to distribute the MindsEye expandable port to neurosurgeons in the U.S.
    MindsEye Expandable Port is the world's first expandable port providing deep brain access in neurosurgery.
  • "Mizuho's mission is to deliver the best devices to neurosurgeons," said William Delaney, vice president of sales at Mizuho America.
  • The MindsEye expandable port has raised the bar for standard of care in neurosurgery and will improve patient outcomes."

Largest Study of Brain Tumor "Keyhole" Surgery for Meningiomas

Retrieved on: 
Thursday, August 4, 2022
Meningioma, Hospital, Risk, Radiosurgery, Endoscopy, Human skull symbolism, PNI, Brain, Myocardial infarction, Providence High School, Patient, Embolism, Publication, Cerebrospinal fluid leak, PLOS, Meningitis, MD, Saint John's Health Center, Blood, Neuro, Time, St. Mary's Medical Center (Grand Junction, Colorado), Cranial nerves, Medical imaging, Pharmaceutical industry

SANTA MONICA, Calif., Aug. 4, 2022 /PRNewswire/ -- In a groundbreaking 13-year study, Pacific Neuroscience Institute neurosurgical and otolaryngology surgical teams demonstrated outstanding outcomes with minimally invasive keyhole surgery for the most common primary brain tumor, in the largest such keyhole cohort published to date.

Key Points: 
  • "Patients coming to us with brain tumors are understandably worried about their diagnoses and clinical outcomes," said neurosurgeon Daniel Kelly, MD, PNI director and senior author of the study.
  • "Keyhole surgery aims to limit brain exposure and manipulation, using smaller strategically placed openings without the use of brain retractors and facilitated by gravity assistance and endoscopy.
  • Meningiomas, the most common primary brain tumor, are non-cancerous brain tumors estimated to be diagnosed in approximately 34,000 people in the United States each year.
  • From an overall cohort of 329 patients with meningiomas treated from 2008-21, the study focused on 193 (59%) who underwent 213 keyhole operations.

OXEIA ANNOUNCES POSITIVE INTERIM RESULTS OF PHASE 2 TRIAL FOR OXE103 FOR THE TREATMENT OF CONCUSSIONS

Retrieved on: 
Wednesday, August 3, 2022
Human, Neuro, Appetite, Brain, Children's Mercy Hospital, Patient, Memory, Concussion, Reactive oxygen species, Diffuse axonal injury, Neurology, GLOBE, Medicine, University of Kansas Medical Center, University, University of San Francisco School of Nursing and Health Professions, Traffic barrier, Ghrelin, Cognition, Pharmaceutical industry, Medical device, Nursing

The trial is focusing on treatment for subjects within 28 days of injury who are highly symptomatic at screening.

Key Points: 
  • The trial is focusing on treatment for subjects within 28 days of injury who are highly symptomatic at screening.
  • This group represents the majority of concussion patients who do not seek treatment immediately following their injury.
  • According to Oxeia CEO, Dr. Michael Wyand, I am encouraged by the interim results we are seeing from the trial.
  • The interim data provide hope for an effective treatment for the millions of people who suffer ongoing post-concussion symptoms due to a lack of effective treatment options.

CHA Hollywood Presbyterian Medical Center Joins New TeleStroke Program

Retrieved on: 
Tuesday, August 2, 2022
Health, Telemedicine, Virtual Medicine, Neurology, Hospitals, Health Technology, Managed Care, General Health, Death, Brain, Physician, USC, HIPPA, FACEP, Hospital, CEO, Telehealth, Research, CHA, Neurology, Neuro, National Association Medical Staff Services, Caregiver, MD, Patient, Stroke, Emergency department, Survival, CDC, Program, Korea Disease Control and Prevention Agency, Brain damage, Center, TPA, Pharmaceutical industry

“Working with Keck Medicine of USC stroke neurologists allows our stroke patients to benefit from the real-time expertise of experts with one of the leading programs in the country,” said Dr. Marco Hernandez, MD, FACEP, Medical Director of CHA HPMC Emergency Department. “This will allow patients to receive optimal therapy for their condition -- whether it be conservative therapy, clot-busting drugs, such as TPA or transfer to a comprehensive stroke center for neuro-interventional care.”

Key Points: 
  • CHA Hollywood Presbyterian Medical Center (CHA HPMC) has launched telestroke services to provide timely assessment of stroke and improve the quality of care to its patients through a collaboration with the USC TeleStroke and Neurological Emergency Program.
  • This program allows physicians in the emergency room at CHA HPMC to consult directly with Keck Medicine of USC world-class stroke neurologists.
  • The program is available 24 hours a day, seven days a week for neurological emergencies through a one-click, HIPPA-compliant online telemedicine platform.
  • CHA Hollywood Presbyterian Medical Center (CHA HPMC) is a nationally recognized acute care facility that has cared for Hollywood and its surrounding communities since 1924.

Calidi Biotherapeutics Announces FDA Authorization of IND for a Phase 1 Clinical Trial of NeuroNova in Patients with Recurrent High-Grade Glioma

Retrieved on: 
Tuesday, August 2, 2022
Stem Cells, Biotechnology, FDA, Health, General Health, Oncology, Research, Infectious Diseases, Genetics, Science, Clinical Trials, Sale, PIPE, Food and Drug Administration, NSC, Person, Patient safety, Northwest Biotherapeutics, Adult, Safety, Clinical trial, Neuro, Security (finance), Securities Act of 1933, National Cancer Institute, National Comprehensive Cancer Network, Population, Neurosurgery, Research, U.S. Securities and Exchange Commission, Potyvirus, Prospectus, Cancer, Temozolomide, Technology, Proxy, Oncology, III, Business, Food, SEC, Failure, Board, Degenerative disease, COVID-19, Nature, FDA, Glioma, Brain tumor, Survival, Form, Name, Business architecture, Plan, Radiation, Neoplasm, Private Securities Litigation Reform Act, Risk, GMP, City of Hope, Trial of the century, Patient, Department, Suite, B cell, Regenerative medicine, Pharmaceutical industry, Vaccine, City, Edoc, Hope

The phase 1 physician-sponsored clinical trial will be an open-label, non-randomized, multicenter study.

Key Points: 
  • The phase 1 physician-sponsored clinical trial will be an open-label, non-randomized, multicenter study.
  • Secondary endpoints will evaluate treatment efficacy, including progression-free and overall survival as well as any immune response to NeuroNova.
  • Worldwide, an estimated 270,000 people were diagnosed with a primary brain tumor in 2020, with a five-year survival rate of only 5%.
  • Recurrent glioma patients have poor prognosis with a median survival of less than one year.

Phillip A. Villanueva, MD, ABNS, is being recognized by Continental Who's Who

Retrieved on: 
Tuesday, August 2, 2022
Association, ABNS, Chemistry, University, Awareness, Temple University Hospital, Brain, Neuroscience, Critical care, St. Thomas University (Florida), American Association of Neurological Surgeons, Neurology, American Association, Continental, Multimedia, General surgery, Neuro, Philosophy, Certification, Mentorship, Temple University, Theology, Congress of Neurological Surgeons, St. Thomas University, Biology, Medical degree, American Board of Commissioners for Foreign Missions, Dentistry, Medicine, Neurosurgery, MD, Science

A highly trained neurosurgeon with 47 years of experience in his field, Dr. Villanueva specializes in surgeries for brain injuries and neuro-critical care.

Key Points: 
  • A highly trained neurosurgeon with 47 years of experience in his field, Dr. Villanueva specializes in surgeries for brain injuries and neuro-critical care.
  • For the past eight years, he has served as the Director of Neuro Trauma and Critical Care at Temple University Hospital in Philadelphia, PA.
  • He additionally serves as a Professor of Clinical Neurosurgery at the Lewis Katz School of Medicine at Temple University.
  • Dr. Villanueva is a member of the American Association of Neurological Surgeons, where he sits on the subcommittee for neuro-critical care.